{"id":8398,"date":"2021-12-16T13:27:01","date_gmt":"2021-12-16T18:27:01","guid":{"rendered":"https:\/\/puyapeptide.net\/product\/lisiraglide-cas-320367-13-3-ist-ein-glucagon-aehnlicher-peptid-1-glp-1-rezeptor-agonist\/"},"modified":"2021-12-16T13:27:01","modified_gmt":"2021-12-16T18:27:01","slug":"lisiraglide-cas-320367-13-3-ist-ein-glucagon-aehnlicher-peptid-1-glp-1-rezeptor-agonist","status":"publish","type":"product","link":"https:\/\/puyapeptide.net\/de\/product\/lisiraglide-cas-320367-13-3-ist-ein-glucagon-aehnlicher-peptid-1-glp-1-rezeptor-agonist\/","title":{"rendered":"Lisiraglide CAS 320367-13-3 ist ein Glucagon-\u00e4hnlicher Peptid-1-(GLP-1)-Rezeptor-Agonist"},"content":{"rendered":"

Lisiraglide CAS 320367-13-3 ist ein Glucagon-\u00e4hnlicher Peptid-1-(GLP-1)-Rezeptor-Agonist<\/strong><\/h2>\n

Produktname: Lixisenatide
\nSynonyme: Lixisenatide, >98%;Lixisenatid;Lixisenatid|Lixisenatidacetat;Lixisenatidacetat;Lixisenatide USP\/EP\/BP
\nCAS: 320367-13-3
\nMF: C215H347N61O65S .347N61O
\nMW: 4858.53
\nEINECS:
\nProduktkategorien:
\nMol Datei: 320367-13-3.mol<\/p>\n

Lisiraglide ist ein Glucagon-\u00e4hnliches Peptid-1 (GLP-1) Rezeptoragonist, ein Hormon, das hilft, den Blutzuckerspiegel zu normalisieren. Die Sicherheit und Wirksamkeit des Medikaments wurden in 10 klinischen Studien untersucht, an denen insgesamt 5.400 Patienten mit Typ-2-Diabetes teilnahmen. In diesen Studien wurde Lisiramid sowohl als Monotherapie als auch in Kombination mit anderen von der FDA zugelassenen Diabetesmedikamenten untersucht, darunter Metformin, Sulfonylharnstoffe, Pioglitazon und Basalinsulin. In diesen Studien verbesserte die Anwendung von Lisiramid den glykierten H\u00e4moglobinspiegel (ein Indikator f\u00fcr den Blutzuckerspiegel). Dar\u00fcber hinaus wurden in der Cardiovascular Outcomes Trial mehr als 6.000 Patienten mit Typ-2-Diabetes, bei denen ein Risiko f\u00fcr atherosklerotische Herz-Kreislauf-Erkrankungen besteht, mit Lisiramid oder Placebo behandelt. Die Anwendung von Lisiramid bei diesen Patienten erh\u00f6hte das Risiko von unerw\u00fcnschten kardiovaskul\u00e4ren Ereignissen nicht. Lisiragid darf nicht zur Behandlung von Patienten mit Typ-1-Diabetes oder Patienten mit erh\u00f6hten Keton- oder Urinwerten im Blut (diabetische Ketoazidose) angewendet werden. Die h\u00e4ufigsten Nebenwirkungen von Lisiramid sind \u00dcbelkeit, Erbrechen, Kopfschmerzen, Durchfall und Schwindel. Hypoglyk\u00e4mie ist eine weitere h\u00e4ufige Nebenwirkung bei Patienten, die mit Lisiramid und anderen Antidiabetika wie Sulfonylharnstoffen und\/oder Basalpflanzen behandelt werden. Dar\u00fcber hinaus wurden in klinischen Studien mit Lisiragib schwere \u00dcberempfindlichkeitsreaktionen (einschlie\u00dflich \u00dcberempfindlichkeit) berichtet. Lixisenatide (Lyxumia) wurde 2013 in Europa zur Vermarktung zugelassen und ist eine injizierbare Diabetesbehandlung auf Basis von Lixisenatide, die einmal t\u00e4glich zusammen mit anderen Medikamenten oder Insulin f\u00fcr Patienten verabreicht wird, deren Blutzuckerspiegel nur durch Medikamente kontrolliert werden kann.< &>
\n Hinweis zu Lisiraglide CAS 320367-13-3<\/strong>
\nNur f\u00fcr Forschungszwecke, nicht f\u00fcr den menschlichen Gebrauch<\/p>\n","protected":false},"excerpt":{"rendered":"

Produktname: Lixisenatide
\nAcetat;Lixisenatide USP\/EP\/BP
\nCAS: 320367-13-3
\nMF: C215H347N61O65S
\nMW: 4858.53
\nMol Datei: 320367-13-3.mol<\/p>\n","protected":false},"featured_media":2102,"comment_status":"open","ping_status":"closed","template":"","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}}},"product_brand":[],"product_cat":[343],"product_tag":[1270],"class_list":{"0":"post-8398","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-diabetes-peptid","7":"product_tag-lisiraglide-cas-320367-13-3-is-a-glucagon-like-peptide-1-glp-1-receptor-agonist-de","8":"desktop-align-left","9":"tablet-align-left","10":"mobile-align-left","12":"first","13":"instock","14":"shipping-taxable","15":"product-type-simple"},"_links":{"self":[{"href":"https:\/\/puyapeptide.net\/de\/wp-json\/wp\/v2\/product\/8398","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/puyapeptide.net\/de\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/puyapeptide.net\/de\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/puyapeptide.net\/de\/wp-json\/wp\/v2\/comments?post=8398"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/puyapeptide.net\/de\/wp-json\/wp\/v2\/media\/2102"}],"wp:attachment":[{"href":"https:\/\/puyapeptide.net\/de\/wp-json\/wp\/v2\/media?parent=8398"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/puyapeptide.net\/de\/wp-json\/wp\/v2\/product_brand?post=8398"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/puyapeptide.net\/de\/wp-json\/wp\/v2\/product_cat?post=8398"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/puyapeptide.net\/de\/wp-json\/wp\/v2\/product_tag?post=8398"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}